Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 163-180

  Egbertson, Melissa S ^a   Wai, John S ^a   Cameron, Mark ^a   Scott Hoerrner, R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Global Process Chemistry Merck   (United States)

Author keywords

HIV integrase inhibitors, and MK 0536 discovery HIV 1 integrase strand transfer inhibitor, barrier to mutation; Mutation profiles, virus inhibition tetrahydronaphthyridine integrase strand transfer inhibitors; Novel heterocyclic template, integrase compounds water catalyzed Diels Alder reaction

Indexed keywords

EID: 84860654618     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch12     Document Type: Chapter

References (36)

1. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O. G.; Hazuda, D. J.; et al. Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIVAIDS infection. J. Med. Chem. 2008, 51, 5843-5855.
2. Grinsztejn, B.; Nguyen, B. Y.; Katlama, C.; Gatell, J. M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C. J.; Chen, J.; Harvey, C. M.; Isaacs, R. D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369, 1261-1269.
3. Hazuda, D.; Iwamoto, M.;Wenning, L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Ann. Rev. Pharmacol. Toxicol. 2009, 49, 377-394.
4. Markowitz, M.; Nguyen, B. Y.; Gotuzzo, E.; Mendo, F.; Ratanasuwan, W.; Kovacs, C.; Prada, G.; Morales-Ramirez, J. O.; Crumpacker, C. S.; Isaacs, R. D.; et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Synd. 2007, 46, 125-133.
5. Han,W.; Egbertson, M.;Wai, J. S.; Zhuang, L.; Ruzek, R. D.; Perlow, D. S.; Isaacs, R. C. A.; Cameron, M.; Foster, B. S.; Dolling, U. H.; et al. Preparation of hydroxynaphthyridinediones as HIV integrase inhibitors.WO 2005087768, Sept. 3, 2005.
6. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
7. Selnick, H. G.; Hazuda, D. J.; Egbertson, M.; Guare, J. P.; Wai, J. S.; Young, S. D.; Clark, D. L.; Medina, J. C. Preparation of nitrogen-containing 4-heteroaryl-2,4-dioxobutyric acids useful as HIV integrase inhibitors. Merck & Co., Inc. 99-US12095[9962513], 287, Dec. 9, 1999; WO, June 1, 1999.
8. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
9. Young, S. D.; Egbertson, M.; Pearson, P. G.;Wai, J. S.; Fisher, T. E.; Guare, J. P.; Embrey, M. W.; Tran, L. O.; Zhuang, L.; Vacca, J.; et al. Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid derivatives useful as HIV integrase inhibitors. Merck & Co., Inc. 99-US12093[9962520], 319, Dec. 9, 1999; WO, June 1, 1999.
10. Egbertson, M.; Langford, H. M.; Melamed, J.; Wai, J. S.; Han, W.; Perlow, D. S.; Zhuang, L.; Embrey, M.; Young, S. D. Preparation of N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors for treatment of HIV infection/AIDS. Merck & Co., Inc. 2003-US7671[2003077857], 217, Sept. 25, 2003; WO, Mar. 12, 2003.
11. Anthony, N. J.; Gomez, R. P.; Young, S. D.; Egbertson, M.; Wai, J. S.; Zhuang, L.; Embrey, M.; Tran, L. O.; Melamed, J.; Langford, H. M.; et al. Preparation of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors. Merck & Co., Inc. 2001-US31456[2002030930], 434. Apr. 18, 2002. WO, Oct. 9, 2001.
12. Pace, P.; Di Francesco, M. E.; Gardelli, C.; Harper, S.; Muraglia, E.; Nizi, E.; Orvieto, F.; Petrocchi, A.; Poma, M.; Rowley, M.; et al. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J. Med. Chem. 2007, 50, 2225-2239.
13. Pace, P.; Rowley, M. Integrase inhibitors for the treatment of HIV infection. Curr. Opin. Drug Discov. Dev. 2008, 11, 471-479.
14. Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S.; Payne, L. S.; Guare, J. P., Jr.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456.
15. Zhuang, L.; Wai, J. S.; Payne, L. S.; Young, S. D.; Fisher, T. E.; Embrey, M.; Guare, J. P. Preparation of aza-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors. Merck & Co., Inc. 2001-US42553[2002036734], 189, May 10, 2002; WO, Oct. 9, 2001.
16. Wai, J. S.; Kim, B.; Fisher, T. E.; Zhuang, L.; Embrey, M. W.; Williams, P. D.; Staas, D. D.; Culberson, C.; Lyle, T. A.; Vacca, J. P.; et al. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 5595-5599.
17. Egbertson, M.; Kuo, M. S.; Perlow, D. S.; Langford, H. M.; Melamed, J. Y.; Wai, J. S.; Vacca, J.; Wallace, A.; Leonard, Y.; Hazuda, D.; et al. Potent HIV integrase inhibitor with excellent pharmacokinetics. Abstract of papers, 234th ACS National Meeting, Boston, 2007. Poster 091.
18. Kozikowski, A. P.; Isobe, K. Oxazoles in organic synthesis: some observations on the use of 5-alkoxyoxazoles in the Diels-Alder process. Heterocycles 1978, 9, 1271-1275.
19. Humphrey, G. R.; Miller, R. A.; Maligres, P. E.; Weissman, S. Process for preparing N-substituted hydroxypyrimidinone carboxamides. Merck & Co., Inc. WO 2009088729, 2009.
20. A similar use of alkali metal carbonates is described in Sugahara, M.; Moritani, Y.; Kuroda, T.; Kondo, K.; Shimadzu, H.; Ukita, T. An efficient synthesis of the anti-asthmatic agent T-440: a selective N-alkylation of 2-pyridone. Chem. Pharm. Bull. 2000, 48, 589-591.
21. Ahmed, A.; Bragg, R. A.; Clayden, J.; Lai, L. W.; McCarthy, C.; Pink, J. H.; Westlund, N.; Yasin, S. A. Barriers to rotation about the chiral axis of tertiary aromatic amides. Tetrahedron 1998, 54, 13277-13294.
22. Welch, C. J.; Biba, M.; Pye, P.; Angelaud, R.; Egbertson, M. Serendipitous discovery of a pH-dependant atropisomer bond rotation: Toward a write-protectable chiral molecular switch? J. Chromatogr. B 2008, 875, 118-121.
23. Zhou,Y. S.; Tay, L.K.; Hughes, D.;Donahue, S. Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist. Clin. Pharmacol. 2004, 44, 680-688.
24. Ikeura,Y.; Ishichi,Y.; Tanaka, T.; Fujishima,A.; Murabayashi, M.; Kawada, M.; Ishimaru, T.; Kamo, I.; Doi, T.; Natsugari, H. Axially chiral N-Benzyl-N,7-dimethyl-5-phenyl-1,7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements. J. Med. Chem. 1998, 41, 4232-4239.
25. Halgren, T. A. Merck molecular force field: I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
26. Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S.M.;Wai, J. S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, J. P., Jr.; Egbertson, M. S.; et al.Anaphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Nat. Acad. Sci. USA 2004, 101, 11233-11238.
27. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; Mc-Daniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; et al. L-735,524: an orally bioavailable humanimmunodeficiency-virus type-1 protease inhibitor. Proc. Nat. Acad. Sci. USA 1994, 91, 4096-4100.
28. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.;Mikol,V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Am. Chem. Soc. 1998, 282, 359-368.
29. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Nat. Acad. Sci. USA 2002, 99, 6661-6666.
30. Witmer, M.; Danovich, R. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. Methods 2009, 47, 277-282.
31. Zahm, J. A.; Bera, S.; Pandey, K. K.; Vora, A.; Stillmock, K.; Hazuda, D.; Grandgenett, D. P. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob. Agents Chemother. 2008, 52, 3358-3368.
32. Sato,M.; Motomura, T.;Aramaki,H.; Matsuda, T.;Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.
33. Zeldin, R.; Petruschke, R. A. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 2004, 53, 4-9.
34. Merry, C.; Barry, M. G.; Mulcahy, D.; Ryan, M.; Heavey, J.; Tjia, J. F.; Gibbons, S. E.; Breckenridge, A. M.; Back, D. J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11, F29-F33.
35. 2 atmosphere for 1 or 2 h. The culture was sampled five to six time points over the course of this incubation time. Protein was precipitated from the samples by treatment with a volume of acetonitrile and 0.1% formic acid followed by centrifugation (~ 1800 g). Parent compound was monitored in the supernatant via LC-MS/MS to give percent parent remaining vs. time plots. An elimination rate constant was calculated and then subsequently used to determine in vitro intrinsic clearance values. A similar approach is outlined in Jones, H.M.; Houston, J. B. Drug Metab. Dispos. 2004, 32(9) 973-982.
36. Pye, P.; Angelaud, R. Merck process research. Unpublished results, 2005.